Effects of CKD-602, a new camptothecin anticancer agent, on pregnant does and embryo-fetal development in rabbits

Drug and Chemical Toxicology

Volumn 28, Issue 1, 2005, Pages 35-49

  Chung, Moon Koo ^a   Kim, Jong Choon ^b   Han, Sang Seop ^a  

^a Korea Institute of Toxicology   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Anticancer agent; CKD 602; Embryo lethality; Rabbits; Teratogenicity study

Indexed keywords

BELOTECAN; CAMPTOTHECIN; UNCLASSIFIED DRUG;

ABORTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL INSEMINATION; CESAREAN SECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EMBRYO; EMBRYO DEVELOPMENT; EMBRYO RESORPTION; EMBRYOTOXICITY; FETOTOXICITY; FETUS; FETUS DEATH; FETUS MORTALITY; GESTATIONAL AGE; MALE; NONHUMAN; ORGANOGENESIS; PREGNANCY; RABBIT; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO LOSS; FEMALE; FETAL RESORPTION; INJECTIONS, INTRAVENOUS; LITTER SIZE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PREGNANCY; RABBITS; TERATOGENS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 13244263124     PISSN: 01480545     EISSN: None     Source Type: Journal    
DOI: 10.1081/DCT-200039685     Document Type: Article

References (36)

1. Bleiberg, H., Rothenberg, M. L. (1996). CPT-11: from DNA topology to clinical activity. Semin. Oncol. 23:1-50.
2. Chahoud, I., Ligensa, A., Dietzel, L., Faqi, A. S. (1999). Correlation between maternal toxicity and embryo/fetal effects. Reprod. Toxicol. 13:375-381.
3. Chernoff, N., Rogers, E. H., Kavlock, R. J. (1989). An overview of maternal toxicity and prenatal development: considerations for developmental toxicity hazard assessments. Toxicology 59:111-125.
4. Crul, M. (2003). CKD-602. Chong Kun Dang. Curr. Opin. Investig. Drugs 4:1455-1459.
5. Dahut, W., Harolod, N., Takimoto, C., Allegra, C., Chen, A., Hamilton, J. M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, W., Grem, J. (1996). Phase I and pharmacokinetic study of 9-aminocamptothecin given as a 72-hour infusion in adult cancer patients. J. Clin. Oncol. 14:1236-1244.
6. Dawson, A. B. (1926). A note on the staining of the skeleton of cleared specimens with Alizarin Red S. Stain Technol. 1:123-124.
7. Fassberg, J., Stella, V. J. (1992). A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81:676-684.
8. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T., Block, J. B. (1970). Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep. 54:461-470.
9. Ha, K. W., Oh, H. Y., Heo, O. S., Park, C. H., Sohn, S. J., Han, E. S., Kim, J. W., Kang, I. H., Kang, H. J., Lee, S. J., Hong, C. L., Kim, J. K. (1998). Genotoxicity studies of an anticancer agent of camptothecin series, CKD-602. Environ. Mutag. Carcinog. 18:129-134.
10. Han, J., Cha, S. W., Kim, C. Y., Lee, G. S., Suh, J. E., Kim, J. K., Kim, J. C., Kang, B. H. (2004). Toxicity study of CKD-602, a camptothecin anticancer agent: 5-day repeated intravenous administration in rats. J. Appl. Pharmacol. 12:49-54.
11. Hashimoto, H., Chatterjee, S., Berger, N. A. (1995). Mutagenic activity of topoisomerase I inhibitors. Clin. Cancer Res. 1:369-376.
12. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K., Kingsbury, W. D. (1989). Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32:715-720.
13. Itabashi, M., Inoue, T., Fujii, T. (1990a). Reproduction and developmental studies of CPT-11: study on administration of the test substance during the period of organogenesis in rats. Clin. Rep. 24:125-129.
14. Itabashi, M., Yoshida, K., Suzuki, K., et al. (1990b). Reproduction and developmental studies of CPT-11: study on administration of the test substance during the period of organogenesis in rabbits. Clin. Rep. 24:157-161.
15. Iyer, L., Ratain, M. J. (1998). Clinical pharmacology of camptothecins. Cancer Chemother. Pharmacol. 42:S31-S43.
16. Kavlock, R. J., Chernoff, N., Rogers, E. H. (1985). The effect of acute maternal toxicity on fetal development in the mouse. Teratog. Carcinog. Mutagen. 5:3-13.
17. Khera, K. S. (1985). Maternal toxicity: a possible ethiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species. Teratology 31:129-153.
18. Khera, K. S. (1987). Maternal toxicity in human and animals: effects on fetal development and criteria for detection. Teratog. Carcinog. Mutagen. 7:287-295.
19. Kim, J. C., Bae, J. H., Kim, I. H., Chung, M. K., Han, S. S. (2001). Historical control data for developmental toxicity study in New Zealand White rabbits. Korean J. Lab. Anim. Sci. 17:47-58.
20. Kolimannsberger, C., Mross, K., Jakob, A., Kanz, L., Bokemyer, C. (1999). Topotecan-a novel topoisomerase I inhibitor. Pharmacol. Clin. Exp. Oncol. 56:1-12.
21. Kruskal, W. H., Wallis, W. A. (1952). Use of ranks in one criterion variance analysis. J. Am. Stat. Assoc. 47:614-617.
22. Lee, J. H., Lee, J. M., Kim, J. K., Ahn, S. K., Lee, S. J., Kim, M. Y., Jew, S. S., Park, J. G., Hong, C. I. (1998). Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res. 21:581-590.
23. Lee, J. H., Lee, J. M., Lim, K. H., Kim, J. K., Ahn, S. K., Bang, Y. J., Hong, C. I. (2000). Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann. N. Y. Acad. Sci. 922:324-325.
24. Moertel, C. G., Schutt, A. J., Reitmeier, R. J., Hahn, R. G. (1972). Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56:95-101.
25. Morita, H., Ariyuki, F., Inomata, N., Nishimura, K., Kasegawa, Y., Miyamoto, M., Watanabe, T. (1987). Spontaneous malformations in laboratory animals: frequency of external, internal and skeletal malformations in rats, rabbits and mice. Cong. Anom. 27:147-206.
26. Muggia, F. M., Creven, P. J., Hansen, H. H., Cohen, M. H., Selawry, O. S. (1972). Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880). Cancer Chemother. Rep. 56:515-521.
27. Nagao, T., Yoshimura, S., Saito, Y., Imai, K. (1999). Developmental toxicity of the topoisomerase inhibitor, etoposide, in rabbits after intravenous administration. Teratog. Carcinog. Mutagen. 19:233-241.
28. Ogawa, M. (1999). Novel anticancer drugs in Japan. J. Cancer Res. Clin. Oncol. 125:134-140.
29. O'Leary, J., Muggia, F. M. (1998). Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer 34:1500-1508.
30. Scheffe, H. (1953). A method of judging all contrasts in the analysis of variance. Biometika 40:87-104.
31. Sieber, S. M., Whang-Peng, J., Botkin, C., Knutsen, T. (1978). Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice. Teratology 18:31-48.
32. Stuckhardt, J. L., Poppe, S. M. (1984). Fresh visceral examination of rat and rabbit fetuses used in teratogenicity testing. Teratog. Carcinog. Mutagen. 4:181-188.
33. Takahashi, N., Kai, S., Kohmura, H., Ishikawa, K., Kuroyanagi, K., Hamajima, Y., Ohta, S., Kadota, T., Kawano, S., Ohta, K. (1986a). Reproduction studies of VP 16-213 (II)-oral administration to rats during the period of fetal organogenesis. J. Toxicol. Sci. 11:195-225.
34. Takahashi, N., Kai, S., Kohmura, H., Ishikawa, K., Kuroyanagi, K., Hamajima, Y., Ohta, S., Kadota, T., Kawano, S., Ohta, K. (1986b). Reproduction studies of VP 16-213 (III)-oral administration to rabbits during the period of fetal organogenesis. J. Toxicol. Sci. 11:227-239.
35. Takimoto, C. H., Wright, J., Arbuck, S. G. (1998). Clinical applications of the camptothecins. Biochim. Blophys. Acta 1400:107-119.
36. Wise, L. D., Beck, S. L., Beltrame, D., Beyer, B. K., Chahoud, I., Clark, R., Druga, A. M., Feuston, M. H., Guittin, P., Henwood, S. M., Kimmel, C. A., Lindstrom, P., Palmer, A. K., Petrere, J. A., Solomon, H. M., Yasuda, M., York, R. G. (1997). Terminology of developmental abnormalities in common laboratory animals (Version 1). Teratology 55:249-292.